Antibody–drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the potency of highly cytotoxic agents, potentially reducing the severity of side effects by preferentially targeting their payload to the tumour site. ADCs are being increasingly used in combination with other agents,...
Antibody–drug conjugates (ADCs) are a promising cancer treatment modality that enables the selective delivery of highly cytotoxic payloads to tumours. However, realizing the full potential of this platform necessitates innovative molecular designs to ta
The use of monoclonal antibodies as therapeutic vector was hypothesized by Paul Ehrlich within the concept of the “Magic Bullet” [1]. Remarkable improvements in biology and chemistry led to the development of antibody–drug conjugates (ADCs), a new generation of biotherapeutics that combines the ...
参考文献: [1]Yamazaki, C.M., Yamaguchi, A., Anami, Y. et al. Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance. Nat Commun 12, 3528 (2021).https://doi.org/10.1038/s41467-021-23793-7 声明:研一的组会文献分享,原创解读。鉴于笔者知识...
ADC(Antibody–Drug Conjugates),全称“抗体偶联药物”,是一类抗体、连接头和细胞毒性药物组成的靶向药物『ADC详解系列第一期——靶点篇』
Antibody–drug conjugates are non-native mAb formats classified as next-generation therapeutics inmonoclonal antibody therapy. Their success can be attributed to their ability to combine two complementary approaches in cancer therapy.54In the first approach, the therapeutic such as a mAb functions in ...
Following in the footsteps of the success of antibody drug conjugates (ADCs), ACNPs are only now reaching clinical evaluation. In this review we discuss the success of ADCs and explore the opportunities ACNPs offer, such as broad chemotherapy payload selection, high drug to antibody ratios and ...
Antibody-drug conjugates ADCC: Antibody-dependent cellular cytotoxicity anti-PD1: Anti programmed cell death protein 1 ASCO: American Society of Clinical Oncology BM: Brain metastases CR: Complete response DAR: Drug to antibody ratio DCR: Disease-control rate DOR: Duration of response ...
Antibody–drug conjugates for cancer: poised to deliver?. Nat Rev Drug Discov 9, 665–667 (2010). https://doi.org/10.1038/nrd3270 Download citation Issue DateSeptember 2010 DOIhttps://doi.org/10.1038/nrd3270 Subjects Clinical pharmacology Drug development Drug regulation Targeted therapies This ...
pharmaceutics Review Antibody–Drug Conjugates: Ushering in a New Era of Cancer Therapy Joshua Hurwitz 1,2,† , Lucy Roxana Haggstrom 3,† and Elgene Lim 1,2,* 1 St. Vincent's Clinical School, Faculty of Medicine and Health, University of New South Wales, Kensington, NSW 2053, ...